OBJECTIVES: Transcatheter aortic valve implantation is a treatment strategy for degenerated aortic valve prostheses, but there is some concern regarding valve thrombosis. The optimal anticoagulation strategy for implantation of a transcatheter aortic valve prosthesis remains unclear.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become the dominant therapy for high-risk patients with severe aortic stenosis over the last decade. In the '2017 ESC/EACTS Guidelines for the management of valvular heart disease' from the European Society of Cardiology and the European Association for CardioThoracic Surgery and the corresponding 2014 US guidelines, TAVI is recommended for patients with severe aortic stenosis who are not suitable to undergo conventional surgical aortic valve replacement or who are suitable for surgery but in whom TAVI is favoured by a multidisciplinary heart team whose members are responsible for patient selection, procedural planning and device implantation. Those patients should have a life expectancy >1 year, and the procedure should be likely to improve their quality of life [1, 2] . One of the main lessons that has been learned is the importance of appropriate patient selection by the heart team, who should consider the risk of fewer comorbidities as suggestive of a good outcome in the absence of an established predictive risk score. There is an ongoing discussion of how to treat patients with intermediate or low risk by improving the many initial obstacles and ensuring procedural safety. Despite the recent progress in this field, many questions about transcatheter heart valve durability, modes of failure, long-term clinical outcomes and adjunctive therapies are unanswered. In particular, transcatheter heart valve thrombosis has not been investigated adequately. There are several case reports and studies focused on subclinical transcatheter heart valve thrombosis.
The purpose of this study was to determine different flow properties of the Sapien XT and Sapien S3 TAVI prostheses implanted in Perimount Magna Ease bioprostheses (Edwards Lifesciences LLC, Irvine, CA, USA) as a possible cause of thrombosis.
MATERIALS AND METHODS

Test circuit
Using a proved in vitro incubator model, experiments were performed as previously described [3, 4] . Fresh unpasteurized milk from a local dairy farm was obtained in the early morning. Milk was harvested from the same cows each time to minimize the impact of variabilities in milk biochemistry and the specific influence of a single animal. Milk was heated in a water bath to 37 C and pumped to an atrial chamber; an enzyme was added to ensure the onset of coagulation after 90s (Milk-O-Ren 220XL, ADD FOOD Service GmbH, Ascheberg, Germany) at a rate of 20 ml/min. This rennet was diluted with distilled water at a ratio of 1: 2 to assure a clotting time of 90s and clotting localized to the valve area only. Coming from the atrial chamber, the milk passed through a mechanical mitral valve into an acrylic chamber imitating the left ventricle where pulsatile flow was accomplished by a pneumatically driven membrane at the bottom (70 cycles per minute). Valves were fixed at the top of the test chamber in the aortic position, and the milk was pumped upside through a flexible column mimicking the aorta to an overflow reservoir and a drain for disposal. To stop the clotting, the test circuit was flushed with water at the end of the experimental run and was dismantled so that one could observe and evaluate the valves.
Experimental set-up
Four different prostheses for TAVI were tested: the Sapien XT and Sapien S3 prostheses, each in sizes 23 and 26 (Edwards Lifesciences LLC). The valves were embedded in aortic root models and fixed in a Perimount Magna Ease bioprosthesis (Edwards Lifesciences LLC), sizes 23 and 25, to imitate a TAVI procedure. The Perimount Magna Ease bioprostheses were also tested in separate test series. Valves were run in the test circuit to determine the shortest time needed to identify distinct thrombi macroscopically in a preliminary series. Each valve type and size had to survive at least 5 test runs, to make sure that the results can be statistically evaluated.
Documentation and analysis
Using a Canon AE1 SLR camera for a general view and a stereomicroscope with a magnification of 8 (Carl Zeiss GmbH, Göttingen, Germany) for a detailed view, thrombus formations were photographically documented for each of the 3 leaflets regions.
Sites of visible thrombus-like formations were indexed as follows: deposits in the area of the left commissure, deposits in the area of the right commissure, deposits in the area of the wall (W) and deposits in the area of the sinus (S) (Fig. 1 ). To eliminate misinterpretations, the thrombus-like formations were evaluated by 2 different investigators.
Statistical analysis
Data are presented as mean relative frequency ± standard deviation. Homogeneity of frequency distribution of thrombus formation was tested using the Mann-Whitney rank test and the Kruskal-Wallis test. P-values <0.05 were considered significant. IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA) was used to perform the analysis.
RESULTS
Preliminary experiments indicated that 25 min was needed to detect the first thrombus-like formations in all valves. These thrombus-like formations were similar to the in vivo observations we saw in the explanted Sapien XT and S3 prostheses from redo procedures after TAVI. In the Sapien-S3 prostheses, the thrombus-like formation was like a film, whereas in the XT prostheses, the thrombus-like formation was like cake crumbs.
No initial thrombus-like formation could be found on the Perimount Magna Ease bioprostheses, whereas notable deposits were observed at each of the indexed locations on the TAVI prostheses. On average, 54% of the thrombus-like formations were found in the sinus (XT 23 mm, 57.43%; XT 26 mm, 53.08%; S3 23 mm, 50.56%; S3 26 mm, 56.00%), 28% at the wall area (XT 23 mm, 18.81%; XT 26 mm, 23.85%; S3 23 mm, 32.58%; S3 26 mm, 29.33%), 13.14% at the right commissure (XT 23 mm, 12.87%; XT 26 mm, 13.85%; S3 23 mm, 5.62%; S3 26 mm, 7.33%) and 9.67% at the left commissure (XT 23 mm, 10.89%; XT 26 mm, 9.23%; S3 23 mm, 11.24%; S3 26 mm, 7.33%) (Figs 2 and 3 ). Significant differences were detected between the Sapien-XT and the Sapien-S3 prostheses at the wall area. Both Sapien-S3 prostheses had significantly more thrombus-like formations than the Sapien-XT prostheses in this area (XT 23 mm, n = 18.8; XT 26 mm, n = 31; S3 23 mm, n = 29; S3 26 mm, n = 44; P = 0.001618) ( Table 1 ). Compared to the Perimount Magna Ease prosthesis, which had no thrombus-like formations, the TAVI prostheses had a highly thrombogenic tendency.
DISCUSSION
Over the past years, TAVI has become a standard procedure for patients with severe aortic valve stenosis. Nevertheless, there is a need to answer questions about device durability, modes of failure, long-term clinical outcomes and adjunctive therapies. Among others, risk of stroke and of valve thrombosis is of peculiar interest. The risk of intraprocedural or delayed cerebrovascular events is one of the unsolved problems in TAVI procedures. New ischaemic lesions were detected by magnetic resonance imaging in 68-84% of patients who had TAVI and were associated with clinical stroke in 4% [5] . A statistically significant high rate of cerebrovascular events at 30 days and 1 year, but no difference after 5 years, was seen in patients who had TAVI compared to patients with surgical aortic valve replacement [6, 7] . About half of the strokes occurred intraprocedurally or within 24 h after TAVI and were related to intraprocedural device manipulation and balloon dilatation; about half of the strokes were delayed strokes. New embolic protection devices to avoid strokes during the TAVI procedure have not been proved effective thus far. Delayed strokes may be due to the undetermined antithrombotic management of patients having TAVI. Another issue of concern about the management of anticoagulation is valve thrombosis with reduced leaflet motion, which was detected in the Portico IDE study using 4D computed tomography imaging. In addition, the incidence of valve thrombosis and of leaflet motion was reported at the 2015 EuroPCR and Transcatheter Valve Therapies meetings to be reduced by up to 40%; 43.2% of cases had the Portico (St. Jude Medical Inc., St. Paul, MN, USA) and 42.9%, the Edwards Sapien XT bioprosthesis. The SAVORY study reported reduced leaflet motion both in surgical aortic valve replacement and TAVI (6.7% vs 18.5%; P = 0.43), including all types of aortic bioprostheses. Nevertheless, in 10-15% of patients who had TAVI, reduced leaflet motion was present and was more likely in patients who were not taking warfarin. In most patients, valve thrombosis was asymptomatic and was successfully treated with heparin or warfarin; however, valve dysfunction with a dramatic increase in transvalvular aortic gradients has been reported [8] [9] [10] [11] [12] [13] .
This study characterizes initial flow-induced thrombus-like formations in TAVI prostheses (Sapien-XT and its follow-up model Sapien S3) in an in vitro incubator test circuit using enzymeactivated fresh warm milk. The main findings were an impressive accumulation of thrombus-like formations in both the Sapien-XT and Sapien-3-prostheses, significant differences between these prostheses detected at the wall area and more than half of the thrombus-like formations seen in the sinuses of the valves. These results are associated with the non-physiological flow pattern induced by the structure of the TAVI prostheses, which comprises a stent graft with a cobalt chromium alloy frame and a bovine pericardium tissue. Platelet activation may be promoted by this structure and the stagnant flow with shed vortices and turbulences. Diastolic vortices and washout similar to those with native valves is nearly impossible. Ducci et al. [14] described a significant variation of flow during the early stages of valve opening and during valve closure. A significantly reduced flow activity in the base of the Valsalva sinuses with a permanent stagnation zone can be observed. The increased incidence of ischaemic events reported after transcatheter heart valve implantation could be associated with regions of stagnation with reduced flow. This study underlines the important role of the sinuses in supporting native valve function and their influence on the formation of the flow pattern. Implantation of a TAVI prosthesis divides the Valsalva sinus, modifies the geometry of the chamber and '. . . alters dramatically the flow dynamics in the region,. . .' [14] . Additionally, high shear stresses at the metal struts of the stent may increase the systemic procoagulant activity [15] .
Significant differences between the prostheses were detected at the wall area. Both Sapien 3 prostheses had significantly more thrombus-like formations than the Sapien XT prostheses in this region. The Sapien S3 differs from the Sapien XT in that its outer skirt is made from polyethylene terephthalate and it has a low frame height and enhanced frame geometry. It remains unclear whether the outer skirt leads to a higher tendency towards thrombogenicity. The results of the present study are comparable with the findings of Pache et al. [16] and Leetmaa et al. [17] , who also found a lower frequency of hypoattenuated leaflet thickening in the Sapien XT compared to the Sapien 3. Pache et al. found early hypoattenuated leaflet thickening in 10% of their patients, and Leetmaa et al., in a considerably lower frequency of 4%. On the other hand, Hansson et al. did not find a different risk of thrombosis among Sapien XT and Sapien 3 in 405 consecutive patients (8% vs 6%; P = 0.42).
The patterns of experimental thrombus-like formations were exactly the same as those that we found in explanted prostheses of patients. In the Sapien S3 prostheses, the thrombus-like formation was like a film, whereas in the XT prostheses, the thrombuslike formation was like the crumbs of a cake. Deposits were located extensively in the sinus and wall area (Fig. 4) .
Limitations
The following limitations should be taken into account. Although this model is generally accepted and routinely used, flow patterns might be a little different compared to the in vivo circulation. In this model a low-flow configuration is used to simulate a volume at the lower range of in vivo valves, imitating conditions that seemed to be critical for developing thrombi as a worst-case scenario. Acceleration of development and identification of possible thrombus-like formations were more distinct. Although this root model did not have coronary flow at the sinuses, the characteristics of volume displacement, dimensions and shape of the outflow tract were similar to those found with in vivo valves in order to achieve adequate flow patterns [3, 4] . It must also be mentioned that 2 out of 3 sinuses have coronary ostia. Thus, at least for the non-coronary sinus, the model conditions are appropriate. No differences in thrombus-like formations between the 3 sinuses were evaluated.
Because the added enzyme was applied externally, possible interactions of activation and aggregation could not be investigated. However, the use of blood extracts in the in vitro studies and the absolute necessity of using anticoagulative agents in artificial circulations may strongly influence the experimental results [18] . Other studies have demonstrated analogies in the coagulation of blood and enzyme-activated milk and sufficient evidence of a similar later clotting process [3, 4, 19] . It is nearly impossible to create sufficient in vivo studies because it is almost impossible to observe intracorporal thrombus onset and growth.
Another limitation of this study is the fact that we could not validate whether shear exposure had a different influence on milk clotting and on haemostasis. However, the efficiency of this model is supported by possible clotting sites in flow field analyses and the observed thrombus-like formations compared to in vivo valve thrombosis [3, 4] .
Furthermore, TAVI prostheses were fixed in Perimount Magna Ease bioprostheses to imitate a TAVI procedure in a native aortic valve. This process is comparable to a valve-in-valve procedure in general. On the other hand, anatomically, the leaflets of the Perimount Magna Ease bioprostheses imitated the leaflets of a native valve and were completely 'removed' by fixing the TAVI prostheses. Due to the designs of both the Edwards Sapien XT and S3, in which the outer skirt nearly reached the commissures, there is no possibility of transverse flow to the sinuses. Both Sapien valve models have a 'flow-barrier' that is anatomically exactly the same in both bioprostheses and has the same effect on interruption of the flow and the different vortexes. Therefore, using a bioprosthesis for fixation does not influence the results.
Also important is the fact that a valve-in-valve procedure is usually necessary in a degenerated stenotic valve prosthesis, which is probably at higher risk for thrombosis due to calcification. Therefore, according to our experience, the value of the valve-in-valve procedure with non-calcified leaflets is negligible for anatomical reasons.
CONCLUSIONS
In conclusion, using a model with enzyme-activated milk allows analysis of the initiation of thrombus-like formations on balloonexpandable TAVI prostheses (Sapien XT and Sapien 3) and potentially thrombotic sites in TAVI prostheses. Sapien prostheses seem to have a thrombotic tendency due to their flow properties. More than half of the thrombus-like formations were seen in the sinus. Sapien 3 prostheses had significantly more thrombus-like formations than the Sapien XT prostheses in the wall area. Furthermore, we found different patterns of thrombus-like formations in the Sapien XT and Sapien 3 TAVI prostheses, which were the same in vivo and in vitro.
